Tabernanthalog

Tabernanthalog
Clinical data
Other names	TBG; DLX-007; DLX007
Identifiers
	IUPAC name 8-methoxy-3-methyl-2,4,5,6-tetrahydro-1H-azepino[4,5-b]indole;
CAS Number	2483829-59-8;
PubChem CID	146026994;
ChemSpider	114959868;
CompTox Dashboard (EPA)	DTXSID301336754 ;
Chemical and physical data
Formula	C14H18N2O
Molar mass	230.311 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CCC2=C(CC1)NC3=C2C=CC(=C3)OC;
	InChI InChI=1S/C14H18N2O/c1-16-7-5-12-11-4-3-10(17-2)9-14(11)15-13(12)6-8-16/h3-4,9,15H,5-8H2,1-2H3; Key:FNGNYGCPNKZYOG-UHFFFAOYSA-N;

Tabernanthalog (TBG, DLX-007) is a novel water-soluble, non-toxic ibogalog or simplified analogue of the psychoactive drug tabernanthine first synthesized by David E. Olson at UC Davis.

Tabernanthalog is a non-hallucinogenic serotonin 5-HT_2A receptor agonist. It is also a serotonin 5-HT_2B receptor antagonist. The drug is described as having high selectivity for the serotonin 5-HT₂ receptors. Other targets of the drug include monoamine oxidase A (MAO-A), the α_2A-adrenergic receptor, the serotonin 5-HT_1B and 5-HT_2C receptors, and the serotonin transporter (SERT).

In rodents, it was found to promote structural neural plasticity, reduce drug seeking behavior, and produce antidepressant like effects. It has also been shown that it effectively reduces motivation for heroin and alcohol in rats. This indicates its efficacy in animals with a history of heroin and alcohol polydrug use.

Due to the rapidly-induced and enduring neuroplasticity, tabernanthalog is a member of the class of compounds known as non-hallucinogenic psychoplastogens. This compound, as well as related compounds, are licensed by Delix Therapeutics and are being developed as potential medicines for neuropsychiatric disorders.